​Rapid clinical advances have put gene therapy at the forefront of biomedical research. Across dozens of academic laboratories, biotech startups and pharmaceutical companies, researchers have built a broad pipeline that the Food and Drug Administration expects will soon produce between 10 and 20 cell and gene therapy products each year.

Gene editing, too, has leaped further ahead, fueled by better tools and jumps in the underlying science.

But, over the past year, notable setbacks accompanied gene therapy’s progress, too. Safety scares renewed decades-old questions, while several late-stage treatments disappointed or were delayed.

What lessons have experts in the field learned from the recent ups and downs? How are they adapting? What steps do they see happening next?

Join BioPharma Dive for an exclusive, interactive webinar on May 11, when we’ll dig into these issues with two gene therapy pioneers and an expert panel of gene editing executives.